trending Market Intelligence /marketintelligence/en/news-insights/trending/rE8iaJkH94cgMdcjmPGBOg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Juno lymphoma drug shows high response rates in phase 1 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Juno lymphoma drug shows high response rates in phase 1 trial

Juno Therapeutics Inc.'s JCAR017 demonstrated a reduction in disease in 74% of patients in a phase 1 trial to treat relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

The TRANSCEND study has treated 91 patients who were put into two groups, the core group and the full analysis group. The patients in the core group received two doses of the drug — 100 million cells and 50 million cells.

For the core group, which included 67 patients, the three-month overall response rate was 74%, with 68% of patients showing no signs of the disease. Across doses, 80% of patients with complete response at three months stayed in complete response at six months and 92% of patients in response at six months remain in response as of Oct. 9.

Median duration of response across doses was 9.2 months. However, the median durability of complete response has not been reached.

Juno is jointly developing JCAR017 with Celgene Corp. under a collaboration aimed at developing treatments for patients with cancer and autoimmune diseases using T-cell therapeutic strategies.

The company presented the updated data at the 59th American Society of Hematology annual meeting.